References
1. American College of Obstetricians, Gynecologists’ Committee on
Practice Bulletins-Gynecology. Management of Symptomatic Uterine
Leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol.
2021;137(6):e100-e15.
2. Qin H, Lin Z, Vasquez E, Luan X, Guo F, Xu L. Association between
obesity and the risk of uterine fibroids: a systematic review and
meta-analysis. J Epidemiol Community Health. 2021;75(2):197-204.
3. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of
uterine fibroids. Int J Gynaecol Obstet. 2020;149(1):3-9.
4. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial
cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev.
2013;34(1):130-62.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet.
2005;365(9468):1415-28.
6. Hebbar S, Chaya V, Rai L, Ramachandran A. Factors influencing
endometrial thickness in postmenopausal women. Ann Med Health Sci Res.
2014;4(4):608-14.
7. Januzzi JL, Jr., Butler J, Sattar N, Xu J, Shaw W, Rosenthal N, et
al. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and
Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment
Study. Diabetes Care. 2021;44(1):210-6.
8. Yang Y, Yao S, Ding JM, Chen W, Guo Y. Enhancer-Gene Interaction
Analyses Identified the Epidermal Growth Factor Receptor as a
Susceptibility Gene for Type 2 Diabetes Mellitus. Diabetes Metab J.
2021;45(2):241-50.
9. Jeong IK, Byun JK, Noh J, Kim SW, Chung YS, Park TS, et al. Reference
Ranges of Serum Insulin-Like Growth Factor-I and Insulin-Like Growth
Factor Binding Protein-3: Results from a Multicenter Study in Healthy
Korean Adults. Endocrinol Metab (Seoul). 2020;35(4):954-9.
10. Tak YJ, Lee SY, Park SK, Kim YJ, Lee JG, Jeong DW, et al.
Association between uterine leiomyoma and metabolic syndrome in parous
premenopausal women: A case-control study. Medicine (Baltimore).
2016;95(46):e5325.
11. Tseng CH. Metformin use is associated with a lower risk of uterine
leiomyoma in female type 2 diabetes patients. Ther Adv Endocrinol Metab.
2019;10:2042018819895159.
12. Ciavattini A, Delli Carpini G, Moriconi L, Clemente N, Orici F,
Boschi AC, et al. The association between ultrasound-estimated visceral
fat deposition and uterine fibroids: an observational study. Gynecol
Endocrinol. 2017;33(8):634-7.
13. Sun K, Xie Y, Zhao N, Li Z. A case-control study of the relationship
between visceral fat and development of uterine fibroids. Exp Ther Med.
2019;18(1):404-10.
14. Levey AS, Bilous R, Shlipak MG. CKD and Diabetes: What Can We Learn
From Their Similarities and Differences? Am J Kidney Dis.
2016;67(3):360-3.
15. Takeda T, Sakata M, Isobe A, Miyake A, Nishimoto F, Ota Y, et al.
Relationship between metabolic syndrome and uterine leiomyomas: a
case-control study. Gynecol Obstet Invest. 2008;66(1):14-7.
16. Chiang CH, Chen W, Tsai IJ, Hsu CY, Wang JH, Lin SZ, et al. Diabetes
mellitus risk after hysterectomy: A population-based retrospective
cohort study. Medicine (Baltimore). 2021;100(4):e24468.
17. Kang S, Park YM, Kwon DJ, Chung YJ, Namkung J, Han K, et al.
Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal
Women with Type 2 Diabetes Mellitus. Diabetes Metab J.
2022;46(4):578-91.
18. Oguz SH, Yildiz BO. An Update on Contraception in Polycystic Ovary
Syndrome. Endocrinol Metab (Seoul). 2021;36(2):296-311.
19. Luo J, Manson JE, Urrutia RP, Hendryx M, LeBlanc ES, Margolis KL.
Risk of Diabetes After Hysterectomy With or Without Oophorectomy in
Postmenopausal Women. Am J Epidemiol. 2017;185(9):777-85.
20. Appiah D, Winters SJ, Hornung CA. Bilateral oophorectomy and the
risk of incident diabetes in postmenopausal women. Diabetes Care.
2014;37(3):725-33.
21. Cermik D, Arici A, Taylor HS. Coordinated regulation of HOX gene
expression in myometrium and uterine leiomyoma. Fertil Steril.
2002;78(5):979-84.
22. Harrison-Woolrych ML, Charnock-Jones DS, Smith SK. Quantification of
messenger ribonucleic acid for epidermal growth factor in human
myometrium and leiomyomata using reverse transcriptase polymerase chain
reaction. J Clin Endocrinol Metab. 1994;78(5):1179-84.
23. Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS,
et al. Progesterone receptor messenger ribonucleic acid and protein are
overexpressed in human uterine leiomyomas. Am J Obstet Gynecol.
1993;169(1):78-85.
24. Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C,
et al. The effects of the selective progesterone receptor modulator
asoprisnil on the morphology of uterine tissues after 3 months treatment
in patients with symptomatic uterine leiomyomata. Hum Reprod.
2007;22(6):1696-704.
25. Padmanabhan S, Lee VW, McLean M, Athayde N, Lanzarone V, Khoshnow Q,
et al. The Association of Falling Insulin Requirements With Maternal
Biomarkers and Placental Dysfunction: A Prospective Study of Women With
Preexisting Diabetes in Pregnancy. Diabetes Care. 2017;40(10):1323-30.
26. Ryan AS, Nicklas BJ, Berman DM. Hormone replacement therapy, insulin
sensitivity, and abdominal obesity in postmenopausal women. Diabetes
Care. 2002;25(1):127-33.
27. Picard F, Wanatabe M, Schoonjans K, Lydon J, O’Malley BW, Auwerx J.
Progesterone receptor knockout mice have an improved glucose homeostasis
secondary to beta -cell proliferation. Proc Natl Acad Sci U S A.
2002;99(24):15644-8.